| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
CONSENSUS STATEMENTS |
Department of Medicine (S.M.), Cedars-Sinai Medical Center, Los Angeles, California 90048; Department of Molecular and Clinical Endocrinology and Oncology (A.C.), Federico II University of Naples, 80138 Naples, Italy; Division of Endocrinology and Metabolism (A.B.), University of Michigan Medical Center, Ann Arbor, Michigan 48109; Endocrinology Clinic (M.M.), Feinberg School of Medicine, Northwestern University, Chicago, Illinois 60611; Department of Endocrinology (A.B.G.), St. Bartholomews Hospital, London EC1A 7BE, United Kingdom; Department of Medicine (D.K.), New York University Medical Center, New York, New York 10016; Division of Endocrinology (D.C.), University of North Carolina, Chapel Hill, North Carolina 27599; Assistance Publique-Hôpitaux de Paris (P.C.), Department of Endocrinology and Reproductive Diseases, Hôpital de Bicêtre and Université Paris-Sud 11, Le Kremlin-Bicêtre F-94276, France; Department of Neurosurgery (E.L.), Brigham & Womens Hospital, Boston, Massachusetts 02115; Department of Internal Medicine (J.S.), University of Iowa, Iowa City, Iowa 52242; Department of Medicine (M.L.V.), University of Virginia, Charlottesville, Virginia 22904; Pituitary Research Unit (K.H.), Garvan Institute of Medical Research, Sydney NSW 2010, Australia; and Department of Internal Medicine (A.G.), University of Brescia, 25121 Brescia, Italy
Address all correspondence and requests for reprints to: S. Melmed, M.D., Cedars-Sinai Research Institute, 8700 Beverly Boulevard, Room 2015, Los Angeles, California 90048.
Objective: The Acromegaly Consensus Group reconvened in November 2007 to update guidelines for acromegaly management.
Participants: The meeting participants comprised 68 pituitary specialists, including neurosurgeons and endocrinologists with extensive experience treating patients with acromegaly.
Evidence/Consensus Process: Goals of treatment and the appropriate imaging and biochemical and clinical monitoring of patients with acromegaly were enunciated, based on the available published evidence.
Conclusions: The group developed a consensus on the approach to managing acromegaly including appropriate roles for neurosurgery, medical therapy, and radiation therapy in the management of these patients.
This article has been cited by other articles:
![]() |
A. Colao, R. S. Auriemma, M. Galdiero, G. Lombardi, and R. Pivonello Effects of Initial Therapy for Five Years with Somatostatin Analogs for Acromegaly on Growth Hormone and Insulin-Like Growth Factor-I Levels, Tumor Shrinkage, and Cardiovascular Disease: A Prospective Study J. Clin. Endocrinol. Metab., October 1, 2009; 94(10): 3746 - 3756. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Castinetti, M. Nagai, I. Morange, H. Dufour, P. Caron, P. Chanson, C. Cortet-Rudelli, J.-M. Kuhn, B. Conte-Devolx, J. Regis, et al. Long-Term Results of Stereotactic Radiosurgery in Secretory Pituitary Adenomas J. Clin. Endocrinol. Metab., September 1, 2009; 94(9): 3400 - 3407. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Giustina, S. Bonadonna, G. Bugari, A. Colao, R. Cozzi, S. Cannavo, L. de Marinis, E. degli Uberti, F. Bogazzi, G. Mazziotti, et al. High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomised controlled trial Eur. J. Endocrinol., August 1, 2009; 161(2): 331 - 338. [Abstract] [Full Text] [PDF] |
||||
Read all eLetters
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Endocrinology | Endocrine Reviews | J. Clin. End. & Metab. |
| Molecular Endocrinology | Recent Prog. Horm. Res. | All Endocrine Journals |